Trade NextCure, Inc. - NXTC CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.51 |
Open | 1.54 |
1-Year Change | 2.67% |
Day's Range | 1.39 - 1.57 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 23, 2024 | 1.51 | -0.05 | -3.21% | 1.56 | 1.67 | 1.48 |
Apr 22, 2024 | 1.58 | 0.03 | 1.94% | 1.55 | 1.65 | 1.49 |
Apr 19, 2024 | 1.57 | 0.03 | 1.95% | 1.54 | 1.66 | 1.53 |
Apr 18, 2024 | 1.54 | 0.05 | 3.36% | 1.49 | 1.56 | 1.49 |
Apr 17, 2024 | 1.49 | -0.05 | -3.25% | 1.54 | 1.59 | 1.45 |
Apr 16, 2024 | 1.61 | 0.03 | 1.90% | 1.58 | 1.67 | 1.58 |
Apr 15, 2024 | 1.63 | -0.25 | -13.30% | 1.88 | 1.89 | 1.60 |
Apr 12, 2024 | 1.88 | 0.02 | 1.08% | 1.86 | 1.90 | 1.78 |
Apr 11, 2024 | 1.82 | -0.10 | -5.21% | 1.92 | 2.03 | 1.81 |
Apr 10, 2024 | 1.87 | 0.07 | 3.89% | 1.80 | 1.91 | 1.80 |
Apr 9, 2024 | 1.87 | -0.11 | -5.56% | 1.98 | 1.98 | 1.86 |
Apr 8, 2024 | 1.99 | -0.14 | -6.57% | 2.13 | 2.15 | 1.98 |
Apr 5, 2024 | 2.11 | -0.02 | -0.94% | 2.13 | 2.18 | 2.07 |
Apr 4, 2024 | 2.10 | -0.12 | -5.41% | 2.22 | 2.40 | 2.05 |
Apr 3, 2024 | 2.37 | 0.01 | 0.42% | 2.36 | 2.42 | 2.23 |
Apr 2, 2024 | 2.46 | 0.30 | 13.89% | 2.16 | 2.49 | 1.98 |
Apr 1, 2024 | 2.28 | 0.15 | 7.04% | 2.13 | 2.29 | 2.00 |
Mar 28, 2024 | 2.14 | 0.30 | 16.30% | 1.84 | 2.23 | 1.76 |
Mar 27, 2024 | 1.91 | 0.11 | 6.11% | 1.80 | 1.91 | 1.68 |
Mar 26, 2024 | 1.95 | 0.03 | 1.56% | 1.92 | 1.98 | 1.89 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
NextCure, Inc. Company profile
About NextCure Inc
Nextcure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its product candidates include NC318, NC410, and NC762. Its lead product candidate NC318, is an immunomedicine targeting an immunomodulatory receptor called Siglec-15 (S15). The Company is evaluating NC318 for the treatment of metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). It is conducting Phase II investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Its second product candidate NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor1. Its NC762, is a monoclonal antibody targeting an immunomodulatory molecule called human B7 homolog 4 protein (B7-H4).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, NextCure Inc revenues decreased from $22.4M to $0K. Net loss increased 90% to $69.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income, net decrease of 70% to $1.4M (income), Research and development - Balancing val increase of 6% to $46.1M (expense).
Industry: | Bio Therapeutic Drugs |
9000 Virginia Manor Rd Ste 200
BELTSVILLE
MARYLAND 20705-4214
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com